Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation.

Drug testing and analysis

Patra A, Herrera M, Gutiérrez JM, Mukherjee AK.
PMID: 34089574
Drug Test Anal. 2021 Aug;13(8):1471-1489. doi: 10.1002/dta.3108. Epub 2021 Jun 18.

Snakebite envenomation is a public health problem of high impact, particularly for the developing world. Antivenom, which contains whole or protease-digested immunoglobulin G, purified from the plasma of hyper-immunized animals (mainly horses), is the mainstay for the treatment of...

Cite
Patra A, Herrera M, Gutiérrez JM, et al. The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation. Drug Test Anal. 2021;13(8):1471-1489doi: 10.1002/dta.3108.
Patra, A., Herrera, M., Gutiérrez, J. M., & Mukherjee, A. K. (2021). The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation. Drug testing and analysis, 13(8), 1471-1489. https://doi.org/10.1002/dta.3108
Patra, Aparup, et al. "The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation." Drug testing and analysis vol. 13,8 (2021): 1471-1489. doi: https://doi.org/10.1002/dta.3108
Patra A, Herrera M, Gutiérrez JM, Mukherjee AK. The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation. Drug Test Anal. 2021 Aug;13(8):1471-1489. doi: 10.1002/dta.3108. Epub 2021 Jun 18. PMID: 34089574.
Copy Download .nbib Format: NLM
Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival.

Oncotarget

Brunner SM, Itzel T, Rubner C, Kesselring R, Griesshammer E, Evert M, Teufel A, Schlitt HJ, Fichtner-Feigl S.
PMID: 29050338
Oncotarget. 2017 Aug 09;8(41):71002-71011. doi: 10.18632/oncotarget.20238. eCollection 2017 Sep 19.

BACKGROUND & AIMS: The immunological microenvironment of HCC influences patient outcome, however, the role of B cells remains unclear. This study investigated effects of local B-cell infiltration in HCC cohorts on patient survival and immunological and molecular tumor microenvironment.RESULTS:...

Cite
Brunner SM, Itzel T, Rubner C, et al. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8(41):71002-71011doi: 10.18632/oncotarget.20238.
Brunner, S. M., Itzel, T., Rubner, C., Kesselring, R., Griesshammer, E., Evert, M., Teufel, A., Schlitt, H. J., & Fichtner-Feigl, S. (2017). Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget, 8(41), 71002-71011. https://doi.org/10.18632/oncotarget.20238
Brunner, Stefan M, et al. "Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival." Oncotarget vol. 8,41 (2017): 71002-71011. doi: https://doi.org/10.18632/oncotarget.20238
Brunner SM, Itzel T, Rubner C, Kesselring R, Griesshammer E, Evert M, Teufel A, Schlitt HJ, Fichtner-Feigl S. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017 Aug 09;8(41):71002-71011. doi: 10.18632/oncotarget.20238. eCollection 2017 Sep 19. PMID: 29050338; PMCID: PMC5642613.
Copy Download .nbib Format: NLM
Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt.

AJP reports

Dasgupta S, Aly AM, Jain SK.
PMID: 26929880
AJP Rep. 2016 Mar;6(1):e96-8. doi: 10.1055/s-0035-1567858. Epub 2015 Nov 20.

Introduction Congestive heart failure due to left to right cardiac shunt is usually managed medically with diuretics, angiotensin converting enzyme inhibitors, and, in some cases, with the addition of digoxin. Case We report a 31-week gestation premature male infant...

Cite
Dasgupta S, Aly AM, Jain SK. Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt. AJP Rep. 2015;6(1):e96-8doi: 10.1055/s-0035-1567858.
Dasgupta, S., Aly, A. M., & Jain, S. K. (2016). Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt. AJP reports, 6(1), e96-8. https://doi.org/10.1055/s-0035-1567858
Dasgupta, Soham, et al. "Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt." AJP reports vol. 6,1 (2016): e96-8. doi: https://doi.org/10.1055/s-0035-1567858
Dasgupta S, Aly AM, Jain SK. Junctional Bradycardia as Early Sign of Digoxin Toxicity in a Premature Infant with Congestive Heart Failure due to a Left to Right Shunt. AJP Rep. 2016 Mar;6(1):e96-8. doi: 10.1055/s-0035-1567858. Epub 2015 Nov 20. PMID: 26929880; PMCID: PMC4737622.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries